However, as CSPGs are also components of the interstitial ECM in the healthy adult brain and Fn is also a component of the BBB BM, targeted delivery of ECM-degradation enzymes to MS lesions is a prerequisite to avoid unwanted side effects. This evidence concerns the gene FN1 and myeloid sarcoma.